Subscribe To
ENTBF / Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Content Topics
Psychedelics
Biotech
Startup
Launches
Phase
Study
Ayahuasca s
Active
Ingredient
Stock
ENTBF
ENTBF News
By Benzinga
February 3, 2022
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal
By Benzinga
February 3, 2022
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal
By Benzinga
February 3, 2022
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal
By Benzinga
October 6, 2021
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal
By Benzinga
October 6, 2021
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal
By Benzinga
October 6, 2021
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal